• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Green Spectrophotometric Methods Accurately Quantify Two Antidiabetic Drugs in Fixed-Dose Tablets

by
November 11, 2026
in Chemistry
Reading Time: 6 mins read
0
Green Spectrophotometric Methods Accurately Quantify Two Antidiabetic Drugs in Fixed-Dose Tablets

Green Spectrophotometric Methods Accurately Quantify Two Antidiabetic Drugs in Fixed-Dose Tablets

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Pharmaceutical researchers have developed and validated two separation-free, ratio-manipulating spectrophotometric procedures that successfully resolve the extensive spectral interference between empagliflozin and sitagliptin in fixed-dose commercial formulations. Empagliflozin, an established sodium–glucose co-transporter 2 inhibitor that lowers blood glucose by inhibiting renal glucose reabsorption, is routinely co-formulated with sitagliptin, a dipeptidyl peptidase-4 inhibitor that stimulates glucose-dependent insulin secretion and suppresses glucagon release. Because type 2 diabetes mellitus frequently requires dual therapy to achieve glycemic control when monotherapy proves insufficient, co-formulated tablets have gained broad clinical application. Nevertheless, analyzing both active pharmaceutical ingredients directly via standard ultraviolet–visible spectrophotometry presents a formidable technical challenge because their zero-order absorption spectra overlap substantially across the critical analytical region. Conventional quality-control laboratories frequently rely on reversed-phase high-performance liquid chromatography to circumvent this overlap, but liquid chromatographic protocols demand dedicated instrumentation, sustained mobile-phase delivery, column maintenance, and substantial organic solvent consumption. The newly designed mathematical approaches resolve this shared analytical region entirely within an environmentally benign ethanol medium, establishing accurate quantification without requiring prior physical extraction, chemical derivatization, or chromatographic separation.

To overcome the overlapping absorption profiles, the investigators established two distinct mathematical data-transformation strategies known as ratio difference spectrophotometry and first-derivative ratio spectrophotometry. The underlying principle of ratio-spectrum manipulation involves dividing the zero-order absorption spectrum of a binary mixture by a carefully characterized standard absorption spectrum of one analyte acting as the divisor. This division converts the interfering component into a constant mathematical baseline across the spectrum, thereby isolating the absorption characteristics of the coexisting analyte for quantitative evaluation. The selection of the divisor concentration represents a critical analytical stage, as it directly governs spectral amplitude, noise levels, and curve smoothness. Through systematic optimization, the research team identified an optimal sitagliptin concentration of 80 micrograms per milliliter as the divisor for generating empagliflozin ratio spectra, whereas an empagliflozin concentration of 18 micrograms per milliliter served as the ideal divisor for resolving sitagliptin signals. At these specific divisor levels, the manipulated spectra demonstrated smooth, distortion-free profiles with high signal-to-noise ratios suitable for subsequent mathematical differentiation and subtraction.

In the ratio difference protocol, quantitative measurement depends on calculating the difference between ratio amplitudes recorded at two carefully paired wavelengths. Subtraction of these two amplitudes completely cancels out the constant contribution of the divisor compound, leaving a net signal that is strictly proportional to the concentration of the target drug. For empagliflozin quantification, the researchers selected ratio amplitudes measured at 230 nanometers and 285 nanometers, utilizing the resulting amplitude difference across these points. Sitagliptin determination was achieved by calculating the amplitude difference between 257 nanometers and 209 nanometers. The linear calibration functions demonstrated excellent proportionality across working concentration ranges of 2 to 25 micrograms per milliliter for empagliflozin and 5 to 100 micrograms per milliliter for sitagliptin. Regression analysis yielded coefficients of determination of 0.9999 for empagliflozin, characterized by a slope of 0.0934 and an intercept of minus 0.0016, and 0.9997 for sitagliptin, with a slope of 0.0722 and an intercept of 0.0023, confirming exceptional proportional fidelity across the tested operational boundaries.

The companion first-derivative ratio approach introduces an additional layer of mathematical discrimination by differentiating the recorded ratio spectra with respect to wavelength. First-derivative transformation was performed using an optimized wavelength increment interval of 8 nanometers and an empirical scaling factor of 80. These operational processing settings were established to ensure adequate derivative peak resolution while preventing high-frequency noise amplification from obscuring analyte signals. Following detailed derivative evaluation, analytical wavelengths of 239 nanometers for empagliflozin and 250 nanometers for sitagliptin were selected, as the contribution of the coexisting drug was negligible at these specific positions. Operating over identical concentration intervals of 2 to 25 micrograms per milliliter for empagliflozin and 5 to 100 micrograms per milliliter for sitagliptin, the first-derivative ratio method achieved linear determination coefficients of 0.9998 for both compounds. The corresponding regression parameters produced a slope of minus 0.0206 with an intercept of 0.0019 for empagliflozin, alongside a slope of 0.0072 with an intercept of minus 0.0020 for sitagliptin, demonstrating robust mathematical resolution without requiring physical phase separation.

Method validation was conducted systematically in accordance with International Council for Harmonisation guidelines to evaluate linearity, analytical accuracy, precision, sensitivity, and selectivity. Accuracy assessments performed through comprehensive recovery studies showed mean recoveries of 100.11 percent for empagliflozin and 99.18 percent for sitagliptin using the ratio difference method, compared to 99.74 percent and 99.32 percent, respectively, using the first-derivative ratio protocol. Method precision was demonstrated across both intra-day repeatability and intermediate-precision testing. For the ratio difference procedure, repeatability relative standard deviation values reached 0.761 percent for empagliflozin and 0.504 percent for sitagliptin, while intermediate precision relative standard deviations were 0.979 percent and 0.651 percent. The first-derivative ratio protocol achieved repeatability relative standard deviation figures of 0.452 percent for empagliflozin and 0.653 percent for sitagliptin, with intermediate precision figures measuring 0.814 percent and 0.716 percent. These low variation percentages confirmed excellent methodological reproducibility.

Sensitivity thresholds were derived statistically from calibration curve characteristics using standard slope and intercept variability formulations. For the ratio difference procedure, the calculated limits of detection were 0.326 micrograms per milliliter for empagliflozin and 0.419 micrograms per milliliter for sitagliptin, with corresponding limits of quantification established at 0.978 and 1.257 micrograms per milliliter. The first-derivative ratio method demonstrated comparable sensitivity, yielding limits of detection of 0.324 micrograms per milliliter for empagliflozin and 0.423 micrograms per milliliter for sitagliptin, alongside limits of quantification of 0.972 and 1.269 micrograms per milliliter. Analytical selectivity was challenged against potential formulation excipients by preparing synthetic placebos containing coloring agents declared on commercial packaging, including red ferric oxide, yellow ferric oxide, and titanium dioxide, mixed with common structural additives including microcrystalline cellulose, lactose monohydrate, starch, talc, and magnesium stearate. When extracted with ethanol, filtered through membrane filters, and scanned across the operational spectra, the placebo matrices produced no detectable analytical interference. Fortification of placebo extracts with known analyte amounts produced recoveries between 99.05 and 99.58 percent for empagliflozin and 98.61 to 99.76 percent for sitagliptin, with relative standard deviations remaining below 1.21 percent.

Practical applicability was confirmed by testing commercial Gliempaflozin SITA 25/100 tablets labeled to contain 25 milligrams of empagliflozin and 100 milligrams of sitagliptin per tablet. Standard sample preparation entailed finely grinding ten tablets, sonicating an aliquot representing an average tablet mass of 350 milligrams in 50 milliliters of ethanol for 20 minutes, clarifying through filter paper and a 0.45-micrometer membrane, and making up the volume in ethanol prior to dilution. The resulting assay values exhibited complete agreement with declared label claims. Further validation using the standard addition technique on spiked tablet solutions produced recoveries spanning 99.46 percent to 100.19 percent, accompanied by relative standard deviations not exceeding 1.05 percent, demonstrating that formulation excipients did not induce systematic bias. The analytical data were statistically compared against results from a previously reported reference procedure using Student’s t-tests for accuracy and variance F-tests for precision at a 95 percent confidence level. For empagliflozin, experimental t-values were 0.581 for ratio difference and 0.753 for first-derivative ratio against a tabulated critical limit of 2.306, while F-values measured 2.12 and 1.33 against a tabulated threshold of 6.388. Sitagliptin determinations yielded t-values of 0.612 and 0.796 alongside F-values of 1.85 and 4.24, confirming no statistically significant difference between the proposed and established reference methods.

A broader comparative analysis illustrates how the proposed mathematical techniques differentiate themselves from previously documented methods for simultaneously analyzing this drug combination. Earlier simultaneous-equation ultraviolet spectrophotometry operated over a substantially higher linear range of 50 to 250 micrograms per milliliter in a binary methanol solvent mixture, relying entirely on absorptivity coefficient ratios at 267 and 276.2 nanometers where spectral overlap remained problematic. In contrast, the newly introduced procedures extend working analytical boundaries toward significantly lower concentrations, enabling reliable quantification down to 2 micrograms per milliliter for empagliflozin and 5 micrograms per milliliter for sitagliptin. Furthermore, when contrasted with established reversed-phase high-performance liquid chromatography using C18 columns and methanol-acid mobile phases, which require continuous solvent pumps, chromatographic columns, and extended run times, the spectrophotometric protocols eliminate instrumental complexity and column maintenance while achieving equivalent quantitative reliability.

To rigorously verify environmental, operational, and performance credentials, the researchers benchmarked the proposed procedures against five complementary greenness and applicability assessment frameworks. Under the Carbon Footprint Reduction Index, the proposed methods scored 85 compared to 74 for the reported simultaneous-equation method, reflecting substantial carbon savings gained from avoiding chromatographic infrastructure and utilizing ethanol rather than methanol. Evaluation with the Complex Modified Green Analytical Procedure Index yielded a score of 80 versus 71, reflecting reduced operational hazards, minimal waste generation, and simple extraction steps. The Click Analytical Chemistry Index registered an 85 to 76 advantage for the new approaches, reinforcing their low resource demands. In assessing operational feasibility, the Blue Applicability Grade Index assigned the proposed protocols a score of 77.5 compared to 72.5 for the reference method, commending the high throughput, minimal sample manipulation, simultaneous dual-analyte detection, and compatibility with standard laboratory instruments.

Comprehensive evaluation under the holistic Whiteness Evaluation for Chemical Analysis framework, which integrates analytical quality, environmental protection, and practical efficiency into unified red, green, and blue assessment dimensions, awarded the proposed methods a score of 89 compared to 72 for the earlier simultaneous-equation method. This metric confirms that the mathematical ratio techniques fall within the high-performance tier of sustainable analytical chemistry without compromising validation rigor or sensitivity. Overall, the ratio difference and first-derivative ratio spectrophotometric methods provide rapid, dependable, and separation-free alternatives for routine commercial quality control. By substituting hazardous chromatographic mobile phases with pure ethanol, streamlining extraction protocols, and achieving wide linear ranges with low limits of detection, these methods offer accessible, low-resource solutions for pharmaceutical monitoring laboratories.

Subject of Research: Green spectrophotometric determination of empagliflozin and sitagliptin in combined pharmaceuticals

Article Title: Green ratio-manipulating spectrophotometric methods for simultaneous determination of empagliflozin and sitagliptin in pharmaceutical formulations

Article References: Mohamad, A. A. A., Almrasy, A. A., Abdelazim, A. H., & Taha, A. S. (2026). Green ratio-manipulating spectrophotometric methods for simultaneous determination of empagliflozin and sitagliptin in pharmaceutical formulations. BMC Chemistry, 20(1), Article 198. https://doi.org/10.1186/s13065-026-01935-6

Image Credits: AI Generated

DOI: 10.1186/s13065-026-01935-6

Keywords: Empagliflozin, Sitagliptin, Ratio difference spectrophotometry, First-derivative ratio spectrophotometry, Spectrophotometric determination, Type 2 diabetes mellitus, Fixed-dose combination, Pharmaceutical quality control, Green analytical chemistry, Ethanol solvent, Spectral overlap, CaFRI index, ComplexMoGAPI, CACI index, BAGI index, WECA framework, Gliempaflozin SITA, Method validation

News Source: Bethany Barker. (November 11, 2026). Green Spectrophotometric Methods Accurately Quantify Two Antidiabetic Drugs in Fixed-Dose Tablets. Scienmag.

Tags: BAGI indexCACI indexCaFRI indexComplexMoGAPIempagliflozinEthanol solventFirst-derivative ratio spectrophotometryfixed-dose combinationGliempaflozin SITAgreen analytical chemistrymethod validationpharmaceutical quality controlRatio difference spectrophotometrysitagliptinSpectral overlapSpectrophotometric determinationtype 2 diabetes mellitusWECA framework
Share12Tweet7Share2ShareShareShare1

Related Posts

Molecular Hybrids Show Multitarget Antidiabetic Potential Across Preclinical Evaluations

Molecular Hybrids Show Multitarget Antidiabetic Potential Across Preclinical Evaluations

November 18, 2026
Optimized Lactoperoxidase Activation Enhances Microbial Stability of Lactose-Free Whey Protein Concentrate

Optimized Lactoperoxidase Activation Enhances Microbial Stability of Lactose-Free Whey Protein Concentrate

November 18, 2026

Vanadyl-Doped Struvite Catalyzes Methylene Blue Degradation Under Mildly Acidic Conditions

November 18, 2026

Nitrogen-Doped Graphene Underlayer Lowers Overpotential in Aluminum-Doped Hematite Water Splitting

November 18, 2026

POPULAR NEWS

  • Spain NTD Drug Study Reveals Severe Territorial Gaps Across Autonomous Communities

    Spain NTD Drug Study Reveals Severe Territorial Gaps Across Autonomous Communities

    29 shares
    Share 12 Tweet 7
  • Guinea Health Study Reveals Severe Workforce Unemployment Despite Rising Professional Training

    29 shares
    Share 12 Tweet 7
  • Rootstock Signaling Networks Dynamically Reprogram Fruit Quality Across Horticultural Crops

    29 shares
    Share 12 Tweet 7
  • Review Uncovers How Group 2 Innate Lymphoid Cells Bridge Neuroimmune Communication

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dynamic Laser Vibration Accurately Measures Longitudinal Stiffness of Moso Bamboo

Structural Modifications Shield High-Temperature Carbon Foams Against Rapid Oxidation Failure

Spinal Cord Injury Index Tracks Intraoperative Trauma During Spinal Cord Tumor Resection

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.